Impact of diabetes mellitus on clinical outcomes in patients affected by Covid-19
Abstract A possible association could exist between type 2 diabetes mellitus (T2DM) and Coronavirus-19 (Covid-19) infection. Indeed, patients with T2DM show high prevalence, severity of disease and mortality during Covid-19 infection. However, the rates of severe disease are significantly higher in...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2020-06-01
|
Series: | Cardiovascular Diabetology |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12933-020-01047-y |
id |
doaj-eaca611a356b41949a03606ad1bc8850 |
---|---|
record_format |
Article |
spelling |
doaj-eaca611a356b41949a03606ad1bc88502020-11-25T03:25:54ZengBMCCardiovascular Diabetology1475-28402020-06-011911410.1186/s12933-020-01047-yImpact of diabetes mellitus on clinical outcomes in patients affected by Covid-19Celestino Sardu0Giuseppe Gargiulo1Giovanni Esposito2Giuseppe Paolisso3Raffaele Marfella4Department of Advanced Medical and Surgical Sciences (DAMSS), University of Campania “Luigi Vanvitelli”Division of Cardiology, Department of Advanced Biomedical Sciences, University Federico II of NaplesDivision of Cardiology, Department of Advanced Biomedical Sciences, University Federico II of NaplesDepartment of Advanced Medical and Surgical Sciences (DAMSS), University of Campania “Luigi Vanvitelli”Department of Advanced Medical and Surgical Sciences (DAMSS), University of Campania “Luigi Vanvitelli”Abstract A possible association could exist between type 2 diabetes mellitus (T2DM) and Coronavirus-19 (Covid-19) infection. Indeed, patients with T2DM show high prevalence, severity of disease and mortality during Covid-19 infection. However, the rates of severe disease are significantly higher in patients with diabetes compared with non-diabetes (34.6% vs. 14.2%; p < 0.001). Similarly, T2DM patients have higher rates of need for Intensive Care Unit (ICU, 37.0% vs. 26.7%; p = 0.028). Thus, about the pneumonia of Covid-19, we might speculate that the complicated alveolar-capillary network of lungs could be targeted by T2DM micro-vascular damage. Therefore, T2DM patients frequently report respiratory symptoms and are at increased risk of several pulmonary diseases. In addition, pro-inflammatory pathways as that involving interleukin 6 (IL-6), could be a severity predictor of lung diseases. Therefore, it looks intuitive to speculate that this condition could explain the growing trend of cases, hospitalization and mortality for patients with T2DM during Covid-19 infection. To date, an ongoing experimental therapy with monoclonal antibody against the IL-6 receptor in Italy seems to have beneficial effects on severe lung disease and prognosis in patients with Covid-19 infection. Therefore, should patients with T2DM be treated with more attention to glycemic control and monoclonal antibody against the IL-6 receptor during the Covid-19 infection?http://link.springer.com/article/10.1186/s12933-020-01047-yType 2 diabetes mellitusCovid-19Micro-vascular diseaseSeveral disease |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Celestino Sardu Giuseppe Gargiulo Giovanni Esposito Giuseppe Paolisso Raffaele Marfella |
spellingShingle |
Celestino Sardu Giuseppe Gargiulo Giovanni Esposito Giuseppe Paolisso Raffaele Marfella Impact of diabetes mellitus on clinical outcomes in patients affected by Covid-19 Cardiovascular Diabetology Type 2 diabetes mellitus Covid-19 Micro-vascular disease Several disease |
author_facet |
Celestino Sardu Giuseppe Gargiulo Giovanni Esposito Giuseppe Paolisso Raffaele Marfella |
author_sort |
Celestino Sardu |
title |
Impact of diabetes mellitus on clinical outcomes in patients affected by Covid-19 |
title_short |
Impact of diabetes mellitus on clinical outcomes in patients affected by Covid-19 |
title_full |
Impact of diabetes mellitus on clinical outcomes in patients affected by Covid-19 |
title_fullStr |
Impact of diabetes mellitus on clinical outcomes in patients affected by Covid-19 |
title_full_unstemmed |
Impact of diabetes mellitus on clinical outcomes in patients affected by Covid-19 |
title_sort |
impact of diabetes mellitus on clinical outcomes in patients affected by covid-19 |
publisher |
BMC |
series |
Cardiovascular Diabetology |
issn |
1475-2840 |
publishDate |
2020-06-01 |
description |
Abstract A possible association could exist between type 2 diabetes mellitus (T2DM) and Coronavirus-19 (Covid-19) infection. Indeed, patients with T2DM show high prevalence, severity of disease and mortality during Covid-19 infection. However, the rates of severe disease are significantly higher in patients with diabetes compared with non-diabetes (34.6% vs. 14.2%; p < 0.001). Similarly, T2DM patients have higher rates of need for Intensive Care Unit (ICU, 37.0% vs. 26.7%; p = 0.028). Thus, about the pneumonia of Covid-19, we might speculate that the complicated alveolar-capillary network of lungs could be targeted by T2DM micro-vascular damage. Therefore, T2DM patients frequently report respiratory symptoms and are at increased risk of several pulmonary diseases. In addition, pro-inflammatory pathways as that involving interleukin 6 (IL-6), could be a severity predictor of lung diseases. Therefore, it looks intuitive to speculate that this condition could explain the growing trend of cases, hospitalization and mortality for patients with T2DM during Covid-19 infection. To date, an ongoing experimental therapy with monoclonal antibody against the IL-6 receptor in Italy seems to have beneficial effects on severe lung disease and prognosis in patients with Covid-19 infection. Therefore, should patients with T2DM be treated with more attention to glycemic control and monoclonal antibody against the IL-6 receptor during the Covid-19 infection? |
topic |
Type 2 diabetes mellitus Covid-19 Micro-vascular disease Several disease |
url |
http://link.springer.com/article/10.1186/s12933-020-01047-y |
work_keys_str_mv |
AT celestinosardu impactofdiabetesmellitusonclinicaloutcomesinpatientsaffectedbycovid19 AT giuseppegargiulo impactofdiabetesmellitusonclinicaloutcomesinpatientsaffectedbycovid19 AT giovanniesposito impactofdiabetesmellitusonclinicaloutcomesinpatientsaffectedbycovid19 AT giuseppepaolisso impactofdiabetesmellitusonclinicaloutcomesinpatientsaffectedbycovid19 AT raffaelemarfella impactofdiabetesmellitusonclinicaloutcomesinpatientsaffectedbycovid19 |
_version_ |
1724595035971780608 |